Moneycontrol PRO

Hold Sanofi India; target of Rs 6885: ICICI Direct

ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6885 in its research report dated July 27, 2022.

July 29, 2022 / 06:57 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Sanofi India

Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, pain, allergy and epilepsy. Around 70% of sales stem from top 7 brands. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India • Sanofi enjoys strong brand recall in anti-diabetic therapy in India.


We maintain HOLD rating on the stock due to lack of visible growth triggers and ramp up in ex-power brand portfolio. Valued at Rs6885 i.e. 26x P/E on FY24E EPS on Rs 264.8.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Sanofi India - 280722 - icici

Broker Research
first published: Jul 29, 2022 06:57 pm
ISO 27001 - BSI Assurance Mark